Spectrum of Hypercortisolism Presentations

EP: 1.Overview of the CATALYST Study for Hypercortisolism

EP: 2.Defining Difficult to Control Diabetes

EP: 3.CATALYST Trial Study Design

EP: 4.True Prevalence of Hypercortisolism

EP: 5.Coexisting Cardiometabolic Conditions and Hypercortisolism

EP: 6.Engaging Primary Care Clinicians in Screening for Hypercortisolism

Now Viewing

EP: 7.Spectrum of Hypercortisolism Presentations

EP: 8.Mifeprestone for Treatment of Hypercortisolism

EP: 9.Reconsidering Standard of Care for Hypercortisolism

Video content above is prompted by the following:

• Can you discuss the spectrum of hypercortisolism and its various clinical presentations, especially in T2D?
• Based on the prevalence data from the CATALYST study, how should we approach screening of patients for hypercortisolism?
• Are there specific subgroups of patients with T2D who may have a higher prevalence of hypercortisolism?
• Can you talk about testing for hypercortisolism? What tests are recommended for screening and subsequent confirmation?
• Can you explain the dexamethasone suppression test (DST) used in the CATALYST study?